Scientists test new shot to reprogram immune cells in arthritis
NCT ID NCT07349420
Summary
This was an early-stage study to test the safety of a new drug called EF-M2 (Immutalon) for people with moderate-to-severe rheumatoid arthritis. The drug is designed to calm the immune system by changing the behavior of specific inflammatory cells. Forty-eight participants received injections of the drug at different doses over four weeks to see how their bodies reacted and to look for early signs that the treatment might be working.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Center for New Medical Technologies
Novosibirsk, Novosibirsk Oblast, 630090, Russia
Conditions
Explore the condition pages connected to this study.